Literature DB >> 15138399

Update: direct and indirect costs of arthritis and other rheumatic conditions--United States, 1997.

.   

Abstract

The medical and societal impact of arthritis and other rheumatic conditions (AORC) has been characterized with respect to disability, ambulatory care, hospitalization, and economic burden. CDC's estimates of the national and state-specific costs of AORC in the United States in 1997 have been published previously. However, CDC has re-estimated indirect costs by enhancing the statistical methods. This report summarizes the results of that analysis, which indicated that indirect costs were 30.1 billion dollars less than previously estimated. The total cost of AORC in the United States in 1997 was 86.2 billion dollars (including 51.1 billion dollars in direct costs and 35.1 billion dollars in indirect costs), approximately 1% of the U.S. gross domestic product. Total costs attributable to AORC by state ranged from 121 million dollars in Wyoming to 8.4 billion dollars in California. Although indirect costs were lower than estimated previously, costs for arthritis remain high and underscore the need for better interventions to reduce the economic burden of arthritis.

Entities:  

Mesh:

Year:  2004        PMID: 15138399

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   17.586


  9 in total

Review 1.  Cost utility of tumour necrosis factor-α inhibitors for rheumatoid arthritis: an application of Bayesian methods for evidence synthesis in a Markov model.

Authors:  Christine M Nguyen; Mark Bounthavong; Margaret A S Mendes; Melissa L D Christopher; Josephine N Tran; Rashid Kazerooni; Anthony P Morreale
Journal:  Pharmacoeconomics       Date:  2012-07-01       Impact factor: 4.981

Review 2.  Self-management strategies to reduce pain and improve function among older adults in community settings: a review of the evidence.

Authors:  M Carrington Reid; Maria Papaleontiou; Anthony Ong; Risa Breckman; Elaine Wethington; Karl Pillemer
Journal:  Pain Med       Date:  2008-03-11       Impact factor: 3.750

3.  Funding of research on headache disorders by the National Institutes of Health.

Authors:  Todd J Schwedt; Robert E Shapiro
Journal:  Headache       Date:  2009-02       Impact factor: 5.887

4.  Osteoarthritis of the knee at 3.0 T: comparison of a quantitative and a semi-quantitative score for the assessment of the extent of cartilage lesion and bone marrow edema pattern in a 24-month longitudinal study.

Authors:  Robert Stahl; Sapna K Jain; Jürgen Lutz; Bradley T Wyman; Marie-Pierre Hellio Le Graverand-Gastineau; Eric Vignon; Sharmila Majumdar; Thomas M Link
Journal:  Skeletal Radiol       Date:  2011-04-09       Impact factor: 2.199

5.  Prevalence of hip symptoms and radiographic and symptomatic hip osteoarthritis in African Americans and Caucasians: the Johnston County Osteoarthritis Project.

Authors:  Joanne M Jordan; Charles G Helmick; Jordan B Renner; Gheorghe Luta; Anca D Dragomir; Janice Woodard; Fang Fang; Todd A Schwartz; Amanda E Nelson; Lauren M Abbate; Leigh F Callahan; William D Kalsbeek; Marc C Hochberg
Journal:  J Rheumatol       Date:  2009-03-13       Impact factor: 4.666

6.  The impact of momentary pain and fatigue on physical activity in women with osteoarthritis.

Authors:  Susan L Murphy; Dylan M Smith; Daniel J Clauw; Neil B Alexander
Journal:  Arthritis Rheum       Date:  2008-06-15

7.  Rheumatoid lung disease.

Authors:  Kevin K Brown
Journal:  Proc Am Thorac Soc       Date:  2007-08-15

8.  Resistive Exercise for Arthritic Cartilage Health (REACH): a randomized double-blind, sham-exercise controlled trial.

Authors:  Angela K Lange; Benedicte Vanwanseele; Nasim Foroughi; Michael K Baker; Ronald Shnier; Richard M Smith; Maria A Fiatarone Singh
Journal:  BMC Geriatr       Date:  2009-01-13       Impact factor: 3.921

9.  Glucosamine prevents in vitro collagen degradation in chondrocytes by inhibiting advanced lipoxidation reactions and protein oxidation.

Authors:  Moti L Tiku; Haritha Narla; Mohit Jain; Praveen Yalamanchili
Journal:  Arthritis Res Ther       Date:  2007       Impact factor: 5.156

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.